Aquilo Capital, L.P.'s Form 4 filing
Spero Therapeutics, Inc. (SPRO) · filed Sep 15, 2021
- Accession no.
- 0001591986-21-000014
- Filed
- Sep 15, 2021, 7:21 PM ET
- Trade date
- Sep 13-14, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $860.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Aquilo Capital, L.P.CIK 0001491371 | 10% Owner |
| Aquilo Capital Management, LLCCIK 0001591986 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2021 | Common Stock, $0.001 par value | PPurchaseAcquired | +44,210 | $18.56 | +$820,674.65 | 4,426,989 | Indirect | |
| Sep 14, 2021 | Common Stock, $0.001 par value | PPurchaseAcquired | +2,156 | $18.49 | +$39,872.42 | 4,429,145 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.